Search

Your search keyword '"Cagossi, K"' showing total 4 results
Start Over Author "Cagossi, K" Journal breast cancer research and treatment
4 results on '"Cagossi, K"'

3. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Author

Maria Vittoria Dieci, Aicha Goubar, Giancarlo Bisagni, Gaia Griguolo, Daniele Generali, Valentina Guarneri, A. Michelotti, Antonio Frassoldati, Rossana Berardi, Fabio Puglisi, Guido Ficarra, Katia Cagossi, Federico Piacentini, Giuseppe Luigi Banna, Pierfranco Conte, Luigi Cavanna, Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, P., and Guarneri, V.

Subjects
0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Tumor-infiltrating lymphocytes, law.invention, ErbB-2, 0302 clinical medicine, Randomized controlled trial, law, Chemotherapy, Endocrine therapy, Ki67, Neoadjuvant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Humans, Lymphocytes, Tumor-Infiltrating, Middle Aged, Neoadjuvant Therapy, Nitriles, Prospective Studies, Quinazolines, Receptors, Cell Surface, Treatment Outcome, Triazoles, Receptors, 80 and over, Lymphocytes, Prospective cohort study, Adjuvant, Neoadjuvant therapy, Tumor, 030220 oncology & carcinogenesis, Letrozole, Cell Surface, Cohort, Nitrile, Breast Neoplasm, Human, Receptor, medicine.drug, medicine.medical_specialty, Socio-culturale, Tumor-infiltrating lymphocyte, Lapatinib, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocol, business.industry, Quinazoline, medicine.disease, Prospective Studie, 030104 developmental biology, Triazole, business, Biomarkers
Abstract

PURPOSE: The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2- patients who do not achieve a pathological complete response. METHODS: Stromal (Str) TIL were centrally evaluated on samples from diagnostic core-biopsies of HR+/HER2- patients included in two prospective randomized trials: the LETLOB trial (neoadjuvant endocrine-based treatment) and the GIOB trial (neoadjuvant chemotherapy-based treatment). Pre- and post-treatment Ki67 was centrally assessed. RESULTS: StrTIL were evaluable in 111 cases (n = 73 from the LETLOB trial and n = 38 from the GIOB trial). Median StrTIL was 2%. Patients with high StrTIL (StrTIL ≥10%, n = 28) had more frequently breast cancer of ductal histology (p = 0.02), high grade (p = 0.049), and high Ki67 (p = 0.02). After neoadjuvant endocrine treatment (LETLOB cohort), a significant Ki67 suppression (p < 0.01) from pre- to post-treatment was observed in both the low and high StrTIL groups. High StrTIL patients achieve more frequently a relative Ki67 suppression ≥50% from baseline as compared to low StrTIL patients (55 vs. 35%, p non significant). After neoadjuvant chemotherapy (GIOB cohort), a significant Ki67 suppression was observed only for low StrTIL patients (Wilcoxon p = 0.001) and not in the high StrTIL group (p = 0.612). In this cohort, the rate of patients achieving a relative Ki67 suppression ≥50% from baseline was significantly higher in the low vs high StrTIL group (64% vs 10%, p = 0.003). Geometric mean Ki67 suppression was evaluated in each cohort according to StrTIL: the lowest value (-41%) was observed for high StrTIL cases treated with chemotherapy. CONCLUSIONS: This hypothesis-generating study suggests that in HR+/HER2- breast cancer StrTIL at baseline may influence the achievement of a molecular response after neoadjuvant treatment. Further evaluation in large studies is needed, and interaction with the type of treatment warrants to be explored.

Published
2017

4. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.

Author

Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, and Torri V

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Capecitabine therapeutic use, Cyclophosphamide therapeutic use, Female, Humans, Receptor, ErbB-2 genetics, Retrospective Studies, Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms drug therapy
Abstract

Purpose: Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting., Methods: We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrospective cohort study, which collected data of metastatic breast cancer (MBC) patients who have received mCHT between 2011 and 2016. Amongst the 584 patients included in the study, 97 were triple negative. In 40.2% of the TNBC patients, mCHT was the first chemotherapy treatment, whereas 32.9% had received 2 or more lines of treatment for the metastatic disease. 45.4% out of 97 TNBC patients received a vinorelbine (VRL)-based regimen, which resulted in the most used type of mCHT, followed by cyclophosphamide (CTX)-based regimens (30.9%) and capecitabine (CAPE)-based combinations (22.7%)., Results: Overall response rate (ORR) and disease control rate (DCR) were 17.5% and 64.9%, respectively. Median progression free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.9-7.2) and 12.1 months (95% CI: 9.6-16.7). Median PFS was 6.9 months for CAPE-based regimens (95% CI: 5.0-18.4), 6.1 months (95% CI: 4.0-8.9) for CTX-based and 5.3 months (95% CI: 4.1-9.5) for VRL-based ones. Median OS was 18.2 months (95% CI: 9.1-NE) for CAPE-based regimens and 11.8 months for VRL- (95% CI: 9.3-16.7 and CTX-based ones (95%CI: 8.7-52.8). Tumour response, PFS and OS decreased proportionally in later lines., Conclusion: This analysis represents the largest series of TNBC patients treated with mCHT in a real-life setting and provides further insights into the advantages of using this strategy even in this poor prognosis subpopulation., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results